Methods for treating headaches and migraines with sodium voltage-dependent channel alpha subunit 11 (SCN11A) inhibitors
SCN11A inhibitors offer targeted treatment for headaches and migraines by addressing genetic predisposition, enhancing treatment efficacy through personalized administration based on SCN11A genetic analysis.
Patent Information
- Application Number
- JP2024529509
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-20
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-06
Smart Images

Figure 2024541089000001 
Figure 2024541089000002 
Figure 2024541089000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates generally to treating a subject having a headache or migraine with a sodium voltage-dependent channel alpha subunit 11 (SCN11A) inhibitor, and to methods of identifying a subject at high risk for developing a headache or migraine. [Background technology]
[0002] Headaches are a very common condition, and most people experience them at some time in their lives. The main symptom of a headache is pain in the head or face. The pain can be throbbing, constant, sharp, or dull. Headaches can be treated with medication, stress management, and biofeedback. Headache pain results from signals interacting between the brain, blood vessels, and surrounding nerves. When a headache occurs, certain nerves are activated by an unknown mechanism, affecting muscles and blood vessels. These nerves send pain signals to the brain.
[0003] Migraine is the second most common type of primary headache. Migraine symptoms include moderate to severe pain, nausea or vomiting, throbbing or throbbing pain, pain lasting 4 hours to 3 days, sensitivity to light, noise, or odors, and / or upset stomach or abdominal pain. The cause of migraine is not clearly understood.
[0004] Voltage-gated sodium channels are membrane protein complexes that play a fundamental role in the ascending phase of action potentials in most excitable cells. The α subunits mediate voltage-dependent gating and conductance, while the auxiliary β subunits regulate the kinetic properties of the channel and promote membrane localization of the complex. Each α subunit consists of four domains connected by three intracellular loops, and each domain consists of six transmembrane segments as well as intracellular and extracellular linkers. SCN11A is the gene that encodes the α subunit of the voltage-gated sodium channel present in nociceptive (pain-sensing) neurons of the dorsal root ganglion and trigeminal ganglion. Summary of the Invention
[0005] The present disclosure provides a method of treating a subject having or at risk of developing a headache, the method comprising administering to the subject an SCN11A inhibitor. The present disclosure also provides a method of treating a subject having or at risk of developing a migraine, the method comprising administering to the subject an SCN11A inhibitor.
[0006] The disclosure also provides a method of treating a subject with a headache or migraine treating or suppressing therapeutic agent by administration of a headache or migraine prophylactic therapeutic agent, where the subject has a headache or migraine or is at risk of developing a headache or migraine, the method comprising obtaining or having obtained a biological sample from the subject, performing or having performed sequence analysis on the biological sample, determining whether the subject has a genotype that includes a predicted loss-of-function variant nucleic acid molecule of SCN11A, and administering or having administered a standard dose of a headache or migraine treating, preventing, or suppressing therapeutic agent to the subject who is of the SCN11A reference type. and / or administering or continuing to administer to the subject an SCN11A inhibitor, or administering or continuing to administer to the subject who is heterozygous for a predicted loss-of-function variant nucleic acid molecule a therapeutic agent for treating, preventing, or suppressing headache or migraine in an amount equal to or less than the standard dose, and / or administering to the subject an SCN11A inhibitor, or administering or continuing to administer to the subject who is homozygous for a predicted loss-of-function variant nucleic acid molecule a therapeutic agent for treating, preventing, or suppressing headache or migraine in an amount equal to or less than the standard dose, wherein the presence of a genotype having a predicted loss-of-function variant nucleic acid molecule of SCN11A indicates that the subject has a low risk of developing headache or migraine.
[0007] The disclosure also provides a method for identifying a subject at increased risk of developing a headache or migraine, the method comprising determining, or having determined, the presence or absence of a predicted loss-of-function variant nucleic acid molecule of SCN11A in a biological sample taken from the subject, where if the subject is of the SCN11A reference type, the subject has an increased risk of developing a headache or migraine, and where if the subject is heterozygous or homozygous for the predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject has a reduced risk of developing a headache or migraine.
[0008] The present disclosure also provides therapeutic agents for treating, preventing, or suppressing headache or migraine for use in treating and / or preventing headache or migraine in a subject having a predicted loss-of-function variant nucleic acid molecule of SCN11A.
[0009] The present disclosure also provides SCN11A inhibitors for use in treating and / or preventing headache or migraine in a subject who is an SCN11A reference type or is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Unless otherwise indicated, such terms are to be given their ordinary meaning in the art. Other terms that are specifically defined are to be interpreted in a manner consistent with the definitions set forth herein.
[0011] Unless expressly stated otherwise, no method or aspect set forth herein is intended to be construed as requiring that its steps be performed in a particular order. Thus, unless specifically stated by a method claim in the claims or description that the steps should be limited to a particular order, no order is intended to be imposed in any respect. This also applies to any possible implicit criteria of interpretation, including logical matters regarding the arrangement of steps or work flow, general meanings derived from grammatical construction or punctuation, or the number or type of aspects described herein.
[0012] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. As used herein, the term "about" means that the recited numerical values are approximate and that small variations will not significantly affect the practice of the disclosed embodiments. When numerical values are used, unless otherwise indicated by context, the term "about" means that the numerical values can vary by ±10% and remain within the scope of the disclosed embodiments.
[0013] As used herein, the term "comprising" may be replaced with "consisting of" or "consisting essentially of" in certain embodiments, as desired. As used herein, the term "isolated" refers to a nucleic acid molecule or polypeptide, meaning that the nucleic acid molecule or polypeptide is in a state other than its natural environment, e.g., apart from blood and / or animal tissue. In some embodiments, an isolated nucleic acid molecule or polypeptide is substantially free of other nucleic acid molecules or other polypeptides, particularly other nucleic acid molecules or polypeptides of animal origin. In some embodiments, the nucleic acid molecule or polypeptide can be in a highly purified form, i.e., more than 95% pure or more than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same nucleic acid molecule or polypeptide in alternative physical forms, such as dimers or alternatively phosphorylated or derivatized forms.
[0014] As used herein, the terms "nucleic acid," "nucleic acid molecule," "nucleic acid sequence," "polynucleotide," or "oligonucleotide" can include polymeric forms of nucleotides of any length, can include DNA and / or RNA, and can be single-stranded, double-stranded, or multistranded. A strand of a nucleic acid also refers to its complementary strand.
[0015] As used herein, the term "subject" includes any animal, including mammals. Mammals include, but are not limited to, farm animals (e.g., horses, cows, pigs, etc.), companion animals (e.g., dogs, cats, etc.), laboratory animals (e.g., mice, rats, rabbits, etc.), and non-human primates. In some embodiments, the subject is a human. In some embodiments, the human is a patient under the care of a physician.
[0016] The present disclosure has observed that predicted loss-of-function variant nucleic acid molecules of SCN11A (in certain subjects, these variants are homozygous or heterozygous) are associated with a reduced risk of developing headache or migraine. It is believed that predicted loss-of-function variant nucleic acid molecules of SCN11A are not associated with headache or migraine. Therefore, subjects who are SCN11A reference type or heterozygous for predicted loss-of-function variant nucleic acid molecules of SCN11A may be treated with SCN11A inhibitors to suppress or prevent headache or migraine, reduce or prevent symptoms, and / or suppress or prevent the onset of symptoms. It is also believed that such subjects with headache or migraine may be further treated with a therapeutic agent that treats or suppresses headache or migraine.
[0017] For the purpose of this disclosure, a particular subject, such as a human, can be classified as having one of three SCN11A genotypes: i) SCN11A reference type, ii) SCN11A predicted loss-of-function variant nucleic acid molecule heterozygous type, or iii) SCN11A predicted loss-of-function variant nucleic acid molecule homozygous type. If a subject does not have a copy of SCN11A predicted loss-of-function variant nucleic acid molecule, the subject is SCN11A reference type. If a subject has a single copy of SCN11A predicted loss-of-function variant nucleic acid molecule, the subject is heterozygous for SCN11A predicted loss-of-function variant nucleic acid molecule. SCN11A predicted loss-of-function variant nucleic acid molecule is any nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) that encodes a variant SCN11A polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function. The predicted loss-of-function variant nucleic acid molecule of SCN11A can also be any nucleic acid molecule (such as genomic nucleic acid molecule, mRNA molecule, cDNA molecule, etc.) that causes complete loss, reduced expression, or abnormal expression of SCN11A mRNA or polypeptide.Subjects with SCN11A polypeptides with partial loss-of-function (or predicted partial loss-of-function) are hypomorphic for SCN11A.If a subject has two copies (same or different) of the predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject is homozygous for the predicted loss-of-function variant nucleic acid molecule of SCN11A.
[0018] The subject who is genotyped or determined to be SCN11A reference type is at high risk of developing headache or migraine.For the subject who is genotyped or determined to be either SCN11A reference type or heterozygous for SCN11A predicted loss-of-function variant nucleic acid molecule, such subject can be treated with SCN11A inhibitor.
[0019] In any embodiment described herein, the subject of headache or migraine prevention by administering SCN11A inhibitor is any person at risk of developing headache or migraine, including but not limited to subjects with head injury (post-traumatic headache), subjects with genetic predisposition to develop headache or migraine, or subjects with migraine or family history of headache.In addition, the subject may have lifestyle risk factors such as stress, lack of sleep, depression, anxiety, etc.Also, in some embodiments, any subject may be at risk of developing headache or migraine.In some embodiments, administration of SCN11A inhibitor may be performed to prevent further headache or migraine from developing in subjects who already have headache or migraine.
[0020] In any of the embodiments described herein, the predicted loss-of-function variant nucleic acid molecule of SCN11A can be any nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) that encodes an SCN11A variant polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function. In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is any nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, cDNA molecule, etc.) that causes reduced or abnormal expression of SCN11A mRNA or polypeptide. In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is associated with a reduced in vitro response to SCN11A ligand compared to the reference SCN11A. In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is an SCN11A variant nucleic acid molecule that causes or is predicted to cause premature truncation of SCN11A polypeptide compared to the human reference genome sequence. In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is a variant predicted to be damaging by an in vitro prediction algorithm, such as Polyphen, SIFT, or similar algorithm.In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is a variant that causes or is predicted to cause a non-synonymous amino acid substitution in SCN11A nucleic acid molecule, and the allele frequency is less than 1 / 100 alleles in the population that the subject is selected from.In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A is any rare missense variant (allelic frequency <0.1%; or 1 in 1,000 alleles), or any splice site, stop-gain, start-loss, stop-loss, frameshift, in-frame indel, or other frameshift SCN11A variant.
[0021] In any of the embodiments described herein, the predicted loss-of-function polypeptide of SCN11A can be any SCN11A polypeptide having a partial loss of function, a complete loss of function, a predicted partial loss of function, or a predicted complete loss of function.
[0022] In any of the embodiments described herein, the predicted loss-of-function variant nucleic acid molecule of SCN11A may include a mutation at the position of chromosome 3, using the nucleotide sequence of the SCN11A reference genomic nucleic acid molecule (see ENST00000302328.9 at chr3:38845764-39051944 of UCSC Genome Browser on Human Dec. 2013 (GRCh38 / hg38) Assembly) as a reference sequence. The sequence of the SCN11A genomic nucleic acid molecule provided in ENST00000302328.9 at chr3:38845764-39051944 of UCSC Genome Browser on Human Dec. 2013 (GRCh38 / hg38) Assembly is merely an exemplary sequence. Other sequences of the SCN11A genomic nucleic acid molecule are also possible. Exemplary predicted loss-of-function variant nucleic acid molecules of SCN11A include, but are not limited to, the following:
[0023] [Table 1-1]
[0024] [Table 1-2]
[0025] [Table 1-3]
[0026] [Table 1-4]
[0027]
Table 1-5
[0028]
Table 1-6
[0029]
Table 1-7
[0030]
Table 1-8
[0031]
Table 1-9
[0032]
Table 1-10
[0033]
Table 1-11
[0034]
Table 1-12
[0035]
Table 2-1
[0036]
Table 2-2
[0037]
Table 2-3
[0038]
Table 2-4
[0039]
Table 2-5
[0040]
Table 2-6
[0041]
Table 2-7
[0042]
Table 2-8
[0043]
Table 2-9
[0044]
Table 2-10
[0045]
Table 2-11
[0046] Any one or more (i.e., any combination) of the predicted loss-of-function variant nucleic acid molecules of SCN11A described herein can be used in any of the methods described herein to determine whether a subject has an increased or decreased risk of developing headache or migraine. A combination of specific variants can form a mask used in the statistical analysis of a specific correlation between SCN11A and increased or decreased risk of developing headache or migraine. In some embodiments, the mask used in the statistical analysis of a specific correlation between SCN11A and increased or decreased risk of developing headache or migraine can exclude one or more of these predicted loss-of-function variant nucleic acid molecules of SCN11A described herein.
[0047] In any of the embodiments described herein, the subject may have a headache. In any of the embodiments described herein, the subject may be at risk of developing a headache. In some embodiments, the headache is a tension headache, a sinus headache, an ice pick headache, a hunger and / or thirst headache, a cluster headache, a hormonal headache, a caffeine headache, an exertional headache, a hypertensive headache, a post-traumatic headache, a recurrent paroxysmal headache, or a chronic headache. In some embodiments, the headache is a tension headache. In some embodiments, the headache is a sinus headache. In some embodiments, the headache is an ice pick headache. In some embodiments, the headache is a hunger and / or thirst headache. In some embodiments, the headache is a cluster headache. In some embodiments, the headache is a hormonal headache. In some embodiments, the headache is a caffeine headache. In some embodiments, the headache is an exertional headache. In some embodiments, the headache is a hypertensive headache. In some embodiments, the headache is a post-traumatic headache. In some embodiments, the headache is a recurrent paroxysmal headache. In some embodiments, the headache is a chronic headache.
[0048] In any of the embodiments described herein, the subject may have a migraine. In any of the embodiments described herein, the subject may be at risk of developing a migraine. Migraine is a neurological disorder identifiable by pain on one side of the head, as well as nausea and hypersensitivity to light and sound. A sign that a migraine is approaching is the aura that precedes it. Migraine aura can be identified by numbness and visual disturbances such as flashing lights or spots in the field of vision. In some embodiments, the migraine is retinal migraine, ocular migraine, migraine with aura, migraine without aura, hemiplegic migraine, episodic migraine, chronic migraine, or status migraineus. In some embodiments, the migraine is retinal migraine. In some embodiments, the migraine is ocular migraine. In some embodiments, the migraine is migraine with aura. In some embodiments, the migraine is migraine without aura. In some embodiments, the migraine is hemiplegic migraine. In some embodiments, the migraine is episodic migraine. In some embodiments, the migraine is a chronic migraine. In some embodiments, the migraine is status migraineus.
[0049] The present disclosure provides a method of treating a subject having or at risk of developing a headache, the method comprising administering to the subject an SCN11A inhibitor. The present disclosure provides a method of treating a subject having or at risk of developing a migraine, the method comprising administering to the subject an SCN11A inhibitor.
[0050] In some embodiments, the SCN11A inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNA (siRNA), and short hairpin RNA (shRNA). Such inhibitory nucleic acid molecules can be designed to target any region of the SCN11A nucleic acid molecule. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes with a sequence in the SCN11A genomic nucleic acid molecule or mRNA molecule to reduce the expression of SCN11A polypeptide in cells of a subject. In some embodiments, the SCN11A inhibitor comprises an antisense molecule, which hybridizes with the SCN11A genomic nucleic acid molecule or mRNA molecule in cells of a subject to reduce the expression of SCN11A polypeptide. In some embodiments, the SCN11A inhibitor comprises an siRNA that hybridizes with the SCN11A genomic nucleic acid molecule or mRNA molecule to reduce the expression of SCN11A polypeptide in cells of a subject. In some embodiments, the SCN11A inhibitor comprises an shRNA, which hybridizes to a genomic nucleic acid molecule or an mRNA molecule of SCN11A and reduces expression of an SCN11A polypeptide in a cell of a subject.
[0051] The inhibitory nucleic acid molecule may comprise RNA, DNA, or both RNA and DNA. The inhibitory nucleic acid molecule may also be linked or fused to a heterologous nucleic acid sequence or a heterologous label, for example in a vector. For example, the inhibitory nucleic acid molecule may be present as an exogenous donor sequence in or containing a vector that contains the inhibitory nucleic acid molecule and the heterologous nucleic acid sequence. The inhibitory nucleic acid molecule may also be linked or fused to a heterologous label. The label may be directly detectable (e.g., a fluorophore) or indirectly detectable (e.g., a hapten, an enzyme, or a fluorophore quencher). Such labels may be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radioactive labels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The label may also be, for example, a chemiluminescent substance, a metal-containing substance, or an enzyme (where enzyme-dependent secondary signal generation occurs). The term "label" may also refer to a "tag" or hapten that can selectively bind to the conjugated molecule such that the conjugated molecule is subsequently added with a substrate and used to generate a detectable signal. For example, biotin can be used as a tag to bind to the tag with an avidin or streptavidin conjugate of horseradish peroxidase (HRP), and a colorimetric substrate (such as tetramethylbenzidine (TMB)) or a fluorogenic substrate can be used to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3xFLAG, 6xHis or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, epitope tags, or the Fc portion of an immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes and their colorimetric, fluorescent and chemiluminescent substrates, as well as other labels.
[0052] Inhibitory nucleic acid molecules can include, for example, nucleotides, or non-natural or modified nucleotides, such as, for example, nucleotide analogs or nucleotide substitutes. Such nucleotides include nucleotides that contain modified bases, sugars, or phosphate groups, or nucleotides that incorporate non-natural moieties into their structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated nucleotides, aminated nucleotides, deaminated nucleotides, alkylated nucleotides, benzylated nucleotides, and fluorophore-labeled nucleotides.
[0053] The inhibitory nucleic acid molecule may contain one or more nucleotide analogs or nucleotide substitutes. A nucleotide analog is a nucleotide that contains modifications to either the base, sugar, or phosphate moiety. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T / U, as well as different purine or pyrimidine bases, such as pseudouridine, uracil-5-yl, hypoxanthine-9-yl (I), and 2-aminoadenine-9-yl. Modified bases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), cytosine and thymine, ... Examples of uracils and cytosines include, but are not limited to, 4-uracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (such as 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.
[0054] Nucleotide analogs may also include modifications at the sugar moiety. Modifications to the sugar moiety include, but are not limited to, natural and synthetic modifications of ribose and deoxyribose. Sugar modifications include, but are not limited to, the following modifications at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl, O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, where alkyl, alkenyl, and alkynyl are substituted or unsubstituted C 1-10 Alkyl or C 2-10 Alkenyl, and C 2-10 Exemplary 2' sugar modifications also include -O[(CH2) n O] m CH3, -O(CH2) n OCH3, -O(CH2) n NH2, -O(CH2) n CH3, -O(CH2) n -ONH2 and -O(CH2) n ON [(CH2) n Other modifications at the 2' position include, but are not limited to, C 1-10Examples of suitable substituents include, but are not limited to, alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving groups, reporter groups, intercalators, groups for improving the pharmacokinetic properties of oligonucleotides, or groups for improving the pharmacodynamic properties of oligonucleotides, and other substituents with similar properties. Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides, and the 5' position of the 5' terminal nucleotide. Modified sugars can also include those containing modifications at the bridging ring oxygen, such as CH2 and S. Nucleotide sugar analogs can also have sugar mimetics, such as a cyclobutyl moiety in place of the pentofuranosyl sugar.
[0055] Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, phosphate moieties in which the bond between two nucleotides can be modified to contain phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates, such as 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. These phosphate bonds or modified phosphate bonds between two nucleotides can be via 3'-5' or 2'-5' bonds, and the bond can contain reverse polarity, such as 3'-5' to 5'-3', or 2'-5' to 5'-2'. Various salts, mixed salts, and free acid forms are also included. Nucleotide substitutes also include peptide nucleic acids (PNAs).
[0056] In some embodiments, the antisense nucleic acid molecule is a gapmer, whereby the first 1-7 nucleotides of the 5'-end and the 3'-end, respectively, have a 2'-methoxyethyl (2'-MOE) modification. In some embodiments, the first 5 nucleotides of the 5'-end and the 3'-end, respectively, have a 2'-MOE modification. In some embodiments, the first 1-7 nucleotides of the 5'-end and the 3'-end are RNA nucleotides. In some embodiments, the first 5 nucleotides of the 5'-end and the 3'-end are RNA nucleotides. In some embodiments, each of the internucleotide backbone linkages is a phosphorothioate linkage.
[0057] In some embodiments, the siRNA molecule has terminal modification.In some embodiments, the 5'-end of the antisense strand is phosphorylated.In some embodiments, a 5'-phosphate analog that cannot be hydrolyzed, such as 5'-(E)-vinyl-phosphonate, is used.
[0058] In some embodiments, the siRNA molecule has a backbone modification. In some embodiments, modified phosphodiester groups linking consecutive ribose nucleosides have been shown to increase the stability and bioavailability of siRNA in vivo. Non-ester groups (-OH, =O) of the phosphodiester bond can be replaced with sulfur, boron, or acetate to obtain phosphorothioate, boranophosphate, and phosphonoacetate linkages. In addition, the phosphodiester group can be replaced with a phosphotriester to facilitate cellular uptake of the siRNA and retention in serum components by removing its negative charge. In some embodiments, the siRNA molecule has a sugar modification. In some embodiments, the sugar is deprotonated (a reaction catalyzed by exonucleases and endonucleases), allowing the 2'-hydroxyl to act as a nucleophile and attack the adjacent phosphorus of the phosphodiester bond. Such alternatives include 2'-O-methyl, 2'-O-methoxyethyl, and 2'-fluoro modifications.
[0059] In some embodiments, the siRNA molecule has base modifications, in some embodiments, the bases may be replaced with modified bases such as pseudouridine, 5'-methylcytidine, N6-methyladenosine, inosine, and N7-methylguanosine.
[0060] In some embodiments, siRNA molecules are conjugated to lipids.Lipids can be conjugated to the 5'-end or 3'-end of siRNA, and can improve their bioavailability in vivo by associating with serum lipoproteins.Representative lipids include cholesterol and vitamin E, and fatty acids such as palmitic acid and tocopherol.
[0061] In some embodiments, an exemplary siRNA has the following formula: Sense: mN * mN * / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / * mN * / 32FN / Antisense: / 52FN / * / i2FN / * mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN * N * N where "N" is a base, "2F" is a 2'-F modification, "m" is a 2'-O-methyl modification, "I" is an internal base, and * " are phosphorothioate backbone linkages.
[0062] In any of the embodiments described herein, the inhibitory nucleic acid molecule may be administered, for example, as a 1-2 hour intravenous infusion or subcutaneous injection. In any of the embodiments described herein, the inhibitory nucleic acid molecule may be administered at a dose of about 50 mg to about 900 mg, about 100 mg to about 800 mg, about 150 mg to about 700 mg, or about 175 to about 640 mg (mg / kg to mg / m2 based on an assumed body weight of 70 kg and a mg / kg dose multiplier value of 37 for humans). 2 Based on conversion to dose levels, 2.5 to 9.14 mg / kg, 92.5 to 338 mg / m 2 ) may be administered at dosage levels ranging from 0.1 to 100 mg / kg.
[0063] The present disclosure also provides a vector comprising any one or more of the inhibitory nucleic acid molecules. In some embodiments, the vector comprises any one or more of the inhibitory nucleic acid molecules and a heterologous nucleic acid. The vector can be a viral vector or a non-viral vector capable of transporting the nucleic acid molecule. In some embodiments, the vector is a plasmid or a cosmid (e.g., a circular double-stranded DNA to which additional DNA segments can be ligated). In some embodiments, the vector is a viral vector, and additional DNA segments can be ligated into the viral genome. Expression vectors include, but are not limited to, plasmids, cosmids, retroviruses, adenoviruses, adeno-associated viruses (AAV), plant viruses (such as cauliflower mosaic virus and tobacco mosaic virus), yeast artificial chromosomes (YACs), Epstein-Barr (EBV) derived episomes, and other expression vectors known in the art.
[0064] The present disclosure also provides compositions comprising any one or more of the inhibitory nucleic acid molecules. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a carrier and / or excipient. Examples of carriers include, but are not limited to, poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic acid) (PLGA) microspheres, liposomes, micelles, reverse micelles, lipid cochleates, and lipid microtubules. The carrier may comprise a buffered salt solution such as PBS, HBSS, etc.
[0065] In some embodiments, the SCN11A inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks in the recognition sequence(s) or a DNA binding protein that binds to the recognition sequence in the SCN11A genomic nucleic acid molecule. The recognition sequence can be located in the coding region of the SCN11A gene or in a regulatory region that affects the expression of the gene. The recognition sequence of the DNA binding protein or nuclease agent can be located in an intron, exon, promoter, enhancer, regulatory region, or any non-protein coding region. The recognition sequence can include or be close to the start codon of the SCN11A gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon. As another example, two or more nuclease agents can be used, each of which targets a nuclease recognition sequence that includes or is close to the start codon. As another example, two nuclease agents can be used, one targeting a nuclease recognition sequence containing or adjacent to a start codon, and the other targeting a nuclease recognition sequence containing or adjacent to a stop codon, and cleavage by these nuclease agents can delete the coding region between the two nuclease recognition sequences. Any nuclease agent that induces a nick or double-strand break at the desired recognition sequence can be used in the methods and compositions disclosed herein. Any DNA binding protein that binds to the desired recognition sequence can be used in the methods and compositions disclosed herein.
[0066] Suitable nuclease agents and DNA binding proteins for use herein include, but are not limited to, zinc finger proteins or zinc finger nucleases (ZFN) pairs, transcription activator-like effector (TALE) proteins or transcription activator-like effector nucleases (TALEN), or clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) systems. The length of the recognition sequence can vary, but includes, for example, recognition sequences that are about 30-36 bp for zinc finger proteins or ZFN pairs, about 15-18 bp for each ZFN, about 36 bp for TALE proteins or TALEN, and about 20 bp for CRISPR / Cas guide RNA.
[0067] In some embodiments, the CRISPR / Cas system can be used to modify the SCN11A genomic nucleic acid molecule in a cell. The methods and compositions disclosed herein can employ the CRISPR-Cas system by utilizing a CRISPR complex (comprising a guide RNA (gRNA) complexed with a Cas protein) for site-specific cleavage of the SCN11A nucleic acid molecule.
[0068] Cas proteins generally contain at least one RNA recognition domain or RNA binding domain that can interact with gRNA. Cas proteins can also contain nuclease domains (e.g., DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. Suitable Cas proteins include, for example, wild-type Cas9 proteins and wild-type Cpf1 proteins (e.g., FnCpf1). Cas proteins can have full cleavage activity to generate double-stranded breaks in SCN11A genomic nucleic acid molecules, or can be nickases to generate single-stranded breaks in SCN11A genomic nucleic acid molecules. Additional examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Examples of Cas proteins include, but are not limited to, Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, as well as homologs or variants thereof. In some embodiments, a Cas system, such as Cas12a, may have multiple gRNAs encoded by a single crRNA. Cas proteins may also be operably linked to a heterologous polypeptide as a fusion protein. For example, Cas protein can be fused to cleavage domain, epigenetic modification domain, transcription activation domain, or transcription repressor domain.Cas protein can be provided in any form.For example, Cas protein can be provided in the form of protein, for example, Cas protein complexed with gRNA.Alternatively, the Cas protein can be provided in the form of a nucleic acid molecule, e.g., RNA or DNA, encoding the Cas protein.
[0069] In some embodiments, targeted genetic modification of SCN11A genomic nucleic acid molecules can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize with one or more gRNA recognition sequences in a target genomic locus of the SCN11A genomic nucleic acid molecule. The gRNA recognition sequence can include or be adjacent to the start codon of the SCN11A genomic nucleic acid molecule or the stop codon of the SCN11A genomic nucleic acid molecule. For example, the gRNA recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides away from the start codon or the stop codon.
[0070] The gRNA recognition sequence in the target genomic locus in the SCN11A genomic nucleic acid molecule is located near a protospacer adjacent motif (PAM) sequence, which is a 2-6 base pair DNA sequence that immediately follows the DNA sequence targeted by the Cas9 nuclease. A canonical PAM is the sequence 5'-NGG-3', where "N" is any nucleobase followed by two guanine ("G") nucleobases. Although the gRNA can transport Cas9 anywhere in the genome for gene editing, it cannot edit at sites other than the site where Cas9 recognizes the PAM. Additionally, 5'-NGA-3' can be a highly efficient non-canonical PAM for human cells. In general, the PAM is about 2-6 nucleotides downstream of the DNA sequence targeted by the gRNA. The PAM can be adjacent to the gRNA recognition sequence. In some embodiments, the gRNA recognition sequence can be adjacent to the PAM on the 3' end. In some embodiments, the gRNA recognition sequence can be adjacent to the PAM on the 5' end. For example, the cleavage site of the Cas protein can be about 1 to about 10, about 2 to about 5, or 3 base pairs upstream or downstream of the PAM sequence. In some embodiments (e.g., when using Cas9 from S. pyogenes or a closely related Cas9), the PAM sequence of the non-complementary strand can be 5'-NGG-3', where N is any DNA nucleotide and is immediately 3' to the gRNA recognition sequence of the non-complementary strand of the target DNA. Thus, the PAM sequence of the complementary strand is 5'-CCN-3', where N is any DNA nucleotide and is immediately 5' to the gRNA recognition sequence of the complementary strand of the target DNA.
[0071] gRNA is an RNA molecule that binds to Cas protein and targets Cas protein to a specific location in SCN11A genome nucleic acid molecule.Exemplary gRNA is an effective gRNA for inducing Cas enzyme to bind to or cleave SCN11A genome nucleic acid molecule, and the gRNA comprises a DNA targeting segment that hybridizes to the gRNA recognition sequence in SCN11A genome nucleic acid molecule.Exemplary gRNA comprises a DNA targeting segment that hybridizes to the gRNA recognition sequence present in SCN11A genome nucleic acid molecule that includes or is close to the start codon or stop codon. For example, a gRNA can be selected to hybridize with a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides away from a start codon, or with a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides away from a stop codon. Suitable gRNAs may comprise about 17 to about 25 nucleotides, about 17 to about 23 nucleotides, about 18 to about 22 nucleotides, or about 19 to about 21 nucleotides. In some embodiments, a gRNA may comprise 20 nucleotides.
[0072] The Cas protein and gRNA form a complex, and the Cas protein cleaves the target SCN11A genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site inside or outside the nucleic acid sequence present in the target SCN11A genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds. For example, the formation of a CRISPR complex (including a gRNA that hybridizes with a gRNA recognition sequence and forms a complex with a Cas protein) can result in the cleavage of one or both strands within or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or 50 bases or more) the nucleic acid sequence present in the SCN11A genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds.
[0073] Such a method can, for example, produce an SCN11A genomic nucleic acid molecule in which a region of the SCN11A genomic nucleic acid molecule is destroyed, the start codon is destroyed, the stop codon is destroyed, or the coding sequence is destroyed or deleted. Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize with additional gRNA recognition sequences in the target genomic locus of the SCN11A genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (e.g., a second gRNA that hybridizes with a second gRNA recognition sequence), the cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.
[0074] In some embodiments, the therapeutic and / or prophylactic methods further comprise detecting the presence or absence of a predicted loss-of-function variant nucleic acid molecule of SCN11A in a biological sample from the subject. In some embodiments, the predicted loss-of-function variant nucleic acid molecule of SCN11A can be any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein.
[0075] The present disclosure also provides a method of treating a subject with a therapeutic agent that treats or inhibits headache or migraine, where the subject has a headache or migraine or is at risk of developing a headache or migraine. In some embodiments, the method includes obtaining or having obtained a biological sample from the subject, performing or having performed a sequence analysis on the biological sample, and determining whether the subject has a genotype that includes a predicted loss-of-function variant nucleic acid molecule of SCN11A by determining whether the subject has a genotype that includes a predicted loss-of-function variant nucleic acid molecule of SCN11A. In some embodiments, the method further includes administering or continuing to administer a therapeutic agent that treats, prevents, or inhibits headache or migraine at a standard dose to the subject with an SCN11A reference type, and / or administering an SCN11A inhibitor to the subject. In some embodiments, the method further comprises administering or continuing to administer a therapeutic agent for treating, preventing, or inhibiting headache or migraine to a subject who is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A at a dose equal to or less than the standard dose, and / or administering an SCN11A inhibitor to the subject. In some embodiments, the method further comprises administering or continuing to administer a therapeutic agent for treating, preventing, or inhibiting headache or migraine to a subject who is homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A at a dose equal to or less than the standard dose. The presence of a genotype having a predicted loss-of-function variant nucleic acid molecule of SCN11A indicates that the subject is at low risk of developing headache or migraine. In some embodiments, the subject is of the SCN11A reference type. In some embodiments, the subject is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A.
[0076] For subjects who are genotyped or determined to be heterozygous for an SCN11A reference type or predicted loss-of-function variant nucleic acid molecule of SCN11A, such subjects can be administered an SCN11A inhibitor as described herein.
[0077] Detecting the presence or absence of a predicted loss-of-function variant nucleic acid molecule of SCN11A in a biological sample from a subject and / or determining whether a subject has a predicted loss-of-function variant nucleic acid molecule of SCN11A can be performed by any of the methods described herein. In some embodiments, these methods can be performed in vitro. In some embodiments, these methods can be performed in situ. In some embodiments, these methods can be performed in vivo. In any of these embodiments, the nucleic acid molecule can be present in a cell obtained from the subject.
[0078] In some embodiments, if the subject is SCN11A reference type, the subject is administered a standard dose of a therapeutic agent that treats, prevents, or inhibits headaches or migraines. In some embodiments, if the subject is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject is administered a standard dose or a lower dose of a therapeutic agent that treats, prevents, or inhibits headaches or migraines.
[0079] In some embodiments, the method of treatment and / or prevention comprises detecting the presence or absence of a predicted loss-of-function SCN11A polypeptide in a biological sample from a subject. In some embodiments, if the subject does not have a predicted loss-of-function SCN11A polypeptide, the subject is administered a standard dose of a therapeutic agent that treats, prevents, or inhibits headache or migraine. In some embodiments, if the subject has a predicted loss-of-function SCN11A polypeptide, the subject is administered a standard dose or a lower dose of a therapeutic agent that treats, prevents, or inhibits headache or migraine.
[0080] The present disclosure also provides a method of treating a subject with a therapeutic agent for treating or suppressing headache or migraine, where the subject has a headache or migraine or is at risk of developing a headache or migraine. In some embodiments, the method includes obtaining or having obtained a biological sample from the subject, performing or having performed an assay on the biological sample, and determining whether the subject has a predicted loss-of-function polypeptide of SCN11A by determining whether the subject has a predicted loss-of-function polypeptide of SCN11A. If the subject does not have a predicted loss-of-function polypeptide of SCN11A, administer or continue to administer a therapeutic agent for treating or suppressing headache or migraine at a standard dose to the subject, and / or administer an SCN11A inhibitor to the subject. If the subject has a predicted loss-of-function polypeptide of SCN11A, administer or continue to administer a therapeutic agent for treating or suppressing headache or migraine at a standard dose or less to the subject, and / or administer an SCN11A inhibitor to the subject. The presence of a predicted loss-of-function polypeptide of SCN11A indicates that the subject is at a low risk of developing headache or migraine. In some embodiments, the subject has a predicted loss-of-function polypeptide of SCN11A. In some embodiments, the subject does not have a predicted loss-of-function polypeptide of SCN11A.
[0081] The present disclosure also provides a method of preventing a subject from developing a headache or migraine by administering a therapeutic agent that prevents headache or migraine. In some embodiments, the method includes obtaining or having obtained a biological sample from the subject, performing or having performed an assay on the biological sample, and determining whether the subject has a predicted loss-of-function polypeptide of SCN11A by determining whether the subject has a predicted loss-of-function polypeptide of SCN11A. If the subject does not have a predicted loss-of-function polypeptide of SCN11A, administer or continue to administer a therapeutic agent that prevents headache or migraine to the subject at a standard dose, and / or administer an SCN11A inhibitor to the subject. If the subject has a predicted loss-of-function polypeptide of SCN11A, administer or continue to administer a therapeutic agent that prevents headache or migraine to the subject at a standard dose or less, and / or administer an SCN11A inhibitor to the subject. The presence of a predicted loss-of-function polypeptide of SCN11A indicates that the subject is at a low risk of developing a headache or migraine. In some embodiments, the subject has a predicted loss-of-function polypeptide of SCN11A. In some embodiments, the subject does not have a predicted loss-of-function polypeptide of SCN11A.
[0082] Detecting the presence or absence of a predicted loss-of-function SCN11A polypeptide in a biological sample from a subject and / or determining whether a subject has a predicted loss-of-function SCN11A polypeptide can be performed by any of the methods described herein. In some embodiments, these methods can be performed in vitro. In some embodiments, these methods can be performed in situ. In some embodiments, these methods can be performed in vivo. In any of these embodiments, the polypeptide can be present in a cell obtained from the subject.
[0083] In some embodiments, the SCN11A inhibitor is a small molecule. In some embodiments, the SCN11A inhibitor is a non-selective sodium blocker. In some embodiments, the non-selective sodium blocker is lignocaine, mexiletine, or carbamazepine. In some embodiments, the non-selective sodium blocker is lignocaine. In some embodiments, the non-selective sodium blocker is mexiletine. In some embodiments, the non-selective sodium blocker is carbamazepine. In some embodiments, the SCN11A inhibitor is menthol, mibefradil, or an inorganic l(Ca) blocker.
[0084] In some embodiments, the SCN11A inhibitor is an antibody. Examples of therapeutic agents for treating or preventing headaches include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs) (such as aspirin, ibuprofen, fenoprofen, flurbiprofen, ketoprofen, and naproxen sodium), acetaminophen, celecoxib, diclofenac, indomethacin, ketorolac tromethamine, meclofenamate sodium, diflunisal, tolmetin, nabumetone, carisoprodol, orphenadrine citrate, methocarbamol, cyclobenzaprine hydrochloride, metaxalone, prednisone, ergotamine, lithium, propranolol, diltiazem, and opioids, or combinations thereof.
[0085] Examples of therapeutic agents for treating or suppressing migraine headaches include nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen, fenoprofen, flurbiprofen, ketoprofen, and naproxen sodium); acetaminophen; diclofenac; ketorolac; propofol; lasmiditan; combinations of aspirin, acetaminophen, and caffeine; combinations of isometheptene, dichloralphenazone, and acetaminophen; triptans (e.g., almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, donitriptan, sumatriptan, zolmitriptan, LY-334370, and L-694247); ergots (e.g., dihydroergotamine and ergotatriptan); and the like; calcitonin gene-related peptide (CGRP) receptor antagonists (such as, for example, rimegepant, atogepant, ubrogepant, eptinezumab, erenumab, fremanezumab, and galcanezumab); anti-nausea drugs (such as, for example, chlorpromazine, droperidol, metoclopramide, and prochlorperazine); hypertensive drugs (such as, for example, beta-blockers (such as, for example, propranolol, timolol, and metoprolol) and calcium channel blockers (such as, for example, verapamil)); antidepressants (such as, for example, amitriptyline and nortriptyline); anti-epileptic drugs (such as, for example, gabapentin, topiramate, and valproic acid); opioids; barbiturates; feverfew; and botulinum toxin.
[0086] In some embodiments, for subjects who are heterozygous for predicted loss-of-function variant nucleic acid molecules of SCN11A, compared to subjects who are SCN11A reference type (who may receive standard doses), the dose of a therapeutic agent for treating, preventing, or suppressing headache or migraine can be reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% (i.e., less than standard doses). In some embodiments, the dose of a therapeutic agent for treating, preventing, or suppressing headache or migraine can be reduced by about 10%, about 20%, about 30%, about 40%, or about 50%. Furthermore, subjects who are heterozygous for predicted loss-of-function variant nucleic acid molecules of SCN11A can be administered less frequently compared to subjects who are SCN11A reference type.
[0087] In some embodiments, the dose of a therapeutic agent for treating, preventing, or suppressing headaches or migraines can be reduced by about 10%, about 20%, about 30%, about 40%, about 50% for a subject who is homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A compared to a subject who is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A. In some embodiments, the dose of a therapeutic agent for treating, preventing, or suppressing headaches or migraines can be reduced by about 10%, about 20%, about 30%, about 40%, or about 50%. Furthermore, the dose of a therapeutic agent for treating, preventing, or suppressing headaches or migraines can be administered less frequently to a subject who is homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A compared to a subject who is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A.
[0088] Administration of the therapeutic agent and / or SCN11A inhibitor for treating, preventing or suppressing headache or migraine can be repeated, for example, after 1 day, 2 days, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months or 3 months. Repeated administration can be the same dose or different doses. Administration can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. For example, according to a particular dosing regimen, a subject can be treated for an extended period of time, for example, 6 months, 1 year or more.
[0089] Administration of the therapeutic agent and / or SCN11A inhibitor for treating, preventing, or suppressing headache or migraine may be by any suitable route, including, but not limited to, parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. Pharmaceutical compositions for administration are desirably sterile, substantially isotonic, and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., a single dose for administration). Pharmaceutical compositions can be formulated using one or more physiologically and pharmacologic acceptable carriers, diluents, excipients, or adjuvants. The formulation depends on the route of administration selected. The term "pharmaceutical acceptable" means that the carrier, diluent, excipient, or adjuvant is compatible with the other ingredients of the formulation and is not substantially deleterious to the recipient thereof.
[0090] As used herein, the terms "treat," "treating," and "treatment," as well as "prevent," "preventing," and "prevention," refer to eliciting a desired biological response, such as a therapeutic effect and a prophylactic effect, respectively. In some embodiments, the therapeutic effect comprises one or more of: reduction / alleviation of headache or migraine, reduction / alleviation of headache or migraine severity (e.g., reduction or inhibition of headache or migraine onset), reduction / alleviation of symptoms and headache or migraine related effects, delay in onset of symptoms and headache or migraine related effects, reduction in severity of symptoms of headache or migraine related effects, reduction in the number of symptoms and headache or migraine related effects, reduction in latency of symptoms and headache or migraine related effects, improvement in symptoms and headache or migraine related effects, reduction in secondary symptoms, reduction in secondary infections, prevention of headache or migraine recurrence, reduction in the number or frequency of recurrent episodes, increase in the latency between symptom episodes, increase in time to sustained progression, promotion of recovery, or increased effectiveness or reduced resistance to alternative therapeutic agents, and / or increased survival of an affected host animal after administration of the agent or a composition comprising the agent. A prophylactic effect may include complete or partial avoidance / inhibition or delay (e.g., complete or partial avoidance / inhibition or delay, etc.) of the onset / progression of headache or migraine following administration of a therapeutic protocol, and an increase in the survival time of the affected host animal. Treatment of headache or migraine includes treatment of a subject already diagnosed with any form of headache or migraine, at any clinical stage or symptomatic manifestation, delaying the onset or progression or aggravation or worsening of headache or migraine symptoms or signs, and / or preventing and / or reducing the severity of headache or migraine.
[0091] The present disclosure also provides a method for identifying a subject at high risk of developing headache or migraine. In some embodiments, the method includes determining or has already determined the presence or absence of a predicted loss-of-function variant nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, and / or cDNA molecule) of SCN11A in a biological sample taken from a subject. If the subject lacks a predicted loss-of-function variant nucleic acid molecule of SCN11A (i.e., the subject is genotypically categorized as SCN11A reference type), the subject is at high risk of developing headache or migraine. If the subject has a predicted loss-of-function variant nucleic acid molecule of SCN11A (i.e., the subject is heterozygous or homozygous for the predicted loss-of-function variant nucleic acid molecule of SCN11A), the subject is at low risk of developing headache or migraine.
[0092] When a subject has a single copy of a predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject is more protected from developing headaches or migraines than when the subject does not have a copy of a predicted loss-of-function variant nucleic acid molecule of SCN11A. Without intending to be limited to a particular theory or mechanism of action, it is believed that a single copy of a predicted loss-of-function variant nucleic acid molecule of SCN11A (i.e., heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A) protects the subject from developing headaches or migraines, and furthermore, it is believed that having two copies of a predicted loss-of-function variant nucleic acid molecule of SCN11A (i.e., homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A) can further protect the subject from developing headaches or migraines compared to a subject having a single copy. Thus, in some embodiments, a single copy of a predicted loss-of-function variant nucleic acid molecule of SCN11A may not completely protect a subject from developing headache or migraine, but may instead provide partial or incomplete protection. Without wishing to be bound by any particular theory, there may be additional factors or molecules involved in the development of headache or migraine that are still present in a subject having a single copy of a predicted loss-of-function variant nucleic acid molecule of SCN11A, resulting in less than complete protection from developing headache or migraine.
[0093] Determining whether a subject has a predicted loss-of-function variant nucleic acid molecule of SCN11A in a biological sample from the subject and / or determining whether a subject has a predicted loss-of-function variant nucleic acid molecule of SCN11A can be performed by any of the methods described herein. In some embodiments, these methods can be performed in vitro. In some embodiments, these methods can be performed in situ. In some embodiments, these methods can be performed in vivo. In any of these embodiments, the nucleic acid molecule can be present in a cell obtained from the subject.
[0094] In some embodiments, if a subject is identified as being at high risk of developing a headache or migraine, the subject is administered a therapeutic agent for treating, preventing, or suppressing headache or migraine as described herein and / or an SCN11A inhibitor. For example, if a subject is an SCN11A reference type and is therefore at high risk of developing a headache or migraine, the subject is administered an SCN11A inhibitor. In some embodiments, such a subject is also administered a therapeutic agent for treating, preventing, or suppressing headache or migraine. In some embodiments, if a subject is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject is administered a therapeutic agent for treating, preventing, or suppressing headache or migraine at a dose equal to or less than the standard dose, and is also administered an SCN11A inhibitor. In some embodiments, such a subject is also administered a therapeutic agent for treating, preventing, or suppressing headache or migraine. In some embodiments, if the subject is homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A, the subject is administered a therapeutic agent for treating, preventing, or inhibiting headache or migraine at a dose equal to or less than the standard dose. In some embodiments, the subject is SCN11A reference type. In some embodiments, the subject is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A. In some embodiments, the subject is homozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A.
[0095] The present disclosure also provides a method for measuring the total burden or risk score of a subject having two or more SCN11A variant nucleic acid molecules and / or two or more SCN11A variant polypeptides associated with a reduced risk of developing headache or migraine. The total burden is the sum of two or more genetic variants that can be performed in an association analysis with headache or migraine. In some embodiments, the subject is homozygous for one or more SCN11A variant nucleic acid molecules associated with a reduced risk of developing headache or migraine. In some embodiments, the subject is heterozygous for one or more SCN11A variant nucleic acid molecules associated with a reduced risk of developing headache or migraine. If the subject has a lower total burden, the subject is at high risk of developing headache or migraine, and the subject is administered or continues to be administered a headache or migraine therapeutic agent at the same or lower dose as a standard dose, or a headache or migraine therapy, and / or an SCN11A inhibitor. If a subject's total burden is higher, the subject is at lower risk of developing a headache or migraine, and the subject is administered or continues to be administered a standard dose of a headache or migraine medication or headache or migraine therapy. The higher the total burden, the lower the risk of developing a headache or migraine.
[0096] In some embodiments, the total burden of a subject having any two or more SCN11A variant nucleic acid molecules represents the weighted sum of any plurality of SCN11A variant nucleic acid molecules. In some embodiments, the total burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, at least about 1,000, at least about 10,000, at least about 100,000, or at least about 1,000,000 or more genetic variants present in or surrounding (within 10 Mb) the SCN11A gene, and the genetic burden is the number of alleles multiplied by the estimated association for each allele with headache or migraine or related outcome (e.g., the weighted polygenic burden score). In some embodiments, if a subject has a total burden higher than a desired threshold score, the subject is at low risk of developing a headache or migraine. In some embodiments, if a subject has a total burden lower than a desired threshold score, the subject is at high risk of developing a headache or migraine.
[0097] In some embodiments, the total burden may be divided into quintiles, for example, top quintile, second quintile, middle quintile, fourth quintile, and bottom quintile, with the top quintile of total burden corresponding to the lowest risk group and the bottom quintile of total burden corresponding to the highest risk group. In some embodiments, subjects with higher total burdens include those with the highest weighted total burdens, including but not limited to the top 10%, top 20%, top 30%, top 40%, or top 50% total burdens from the subject population. In some embodiments, the genetic variants include genetic variants with associations with headache or migraine in the top 10%, top 20%, top 30%, top 40%, or top 50% p-value range for association. In some embodiments, each of the identified genetic variants is within the range of about 10 -2 , about 10-3 , about 10 -4 , about 10 -5 , about 10 -6 , about 10 -7 , about 10 -8 , about 10 -9 , about 10 -10 , about 10 -11 , about 10 -12 , about 10 -13 , about 10 -14 , or about 10 -15 In some embodiments, the identified genetic variants have an association with headache or migraine with a p-value of 5×10 -8 In some embodiments, the identified genetic variants include genetic variants that have an association with headache or migraine in high-risk subjects relative to the remainder of the reference population, with an odds ratio (OR) of about 1.5 or more, about 1.75 or more, about 2.0 or more, or about 2.25 or more for the top 20% of the distribution; or about 1.5 or more, about 1.75 or more, about 2.0 or more, about 2.25 or more, about 2.5 or more, or about 2.75 or more. In some embodiments, the odds ratio (OR) may range from about 1.0 to about 1.5, about 1.5 to about 2.0, about 2.0 to about 2.5, about 2.5 to about 3.0, about 3.0 to about 3.5, about 3.5 to about 4.0, about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, about 6.5 to about 7.0, or more than 7.0. In some embodiments, the high-risk subject has a total burden in the bottom decile, quintile, or tertile in the reference population. The total burden threshold may be determined based on the nature of the intended practical application and the risk difference that is considered meaningful for that practical application.
[0098] In embodiments of measuring the total burden of SCN11A gene variants associated with headache or migraine, the total burden represents the risk score of developing headache or migraine in a subject.In some embodiments, the total burden or risk score is an mRNA molecule that comprises or is generated from an SCN11A variant genomic nucleic acid molecule that comprises any of the genetic mutations described herein, or is a cDNA molecule that is generated from an mRNA molecule.In some embodiments, the SCN11A gene variants associated with headache or migraine can be combined with additional genetic variants of other genes that are also associated with headache or migraine to determine the total burden in a subject and generate a weighted polygenic risk score (PRS) for developing headache or migraine.In some embodiments, the PRS is an mRNA molecule that comprises or is generated from an SCN11A variant genomic nucleic acid molecule that comprises any of the genetic mutations described herein, or is a cDNA molecule that is generated from an mRNA molecule.
[0099] The present disclosure also provides a method for detecting the presence or absence of a predicted loss-of-function variant genomic nucleic acid molecule (i.e., a genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule generated from an mRNA molecule) of SCN11A in a biological sample from a subject. It is understood that gene sequences within a population, and the mRNA molecules encoded by such genes, may differ due to polymorphisms, such as single nucleotide polymorphisms.
[0100] The biological sample may be derived from any cell, tissue, or biological fluid from a subject. The biological sample may include any clinically relevant tissue, such as bone marrow sample, tumor biopsy, fine needle aspirate, or a sample of bodily fluid, such as blood, gingival crevicular fluid, plasma, serum, lymph, ascites, cyst fluid, or urine. In some cases, the sample includes a buccal swab. The biological sample used in the methods disclosed herein may vary based on the assay format, the nature of the detection method, and the tissue, cell, or extract used as the sample. The biological sample may be processed differently depending on the assay employed. For example, when detecting any predicted loss-of-function variant nucleic acid molecule of SCN11A, a pre-processing designed to isolate or enrich the biological sample for genomic DNA may be employed. A variety of techniques may be used for this purpose. When detecting the level of a predicted loss-of-function variant nucleic acid molecule of SCN11A, various techniques may be used to enrich the biological sample containing mRNA molecules. A variety of methods may be used to detect the presence or level of mRNA molecules or the presence of a specific variant genomic DNA locus.
[0101] In some embodiments, detecting a predicted loss-of-function variant nucleic acid molecule of SCN11A in a subject comprises performing sequence analysis on a biological sample taken from the subject to determine whether an SCN11A genomic nucleic acid molecule in the biological sample, and / or an SCN11A mRNA molecule in the biological sample, and / or an SCN11A cDNA molecule generated from the mRNA molecule in the biological sample contains one or more mutations that cause or are predicted to cause a loss of function (partial or complete).
[0102] In some embodiments, a method for detecting the presence or absence of a predicted loss-of-function variant nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule generated from an mRNA) of SCN11A in a subject comprises performing an assay on a biological sample obtained from the subject, the assay determining whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.
[0103] In some embodiments, the biological sample comprises cells or cell lysates.Such method may further comprise, for example, taking biological sample from subject that comprises SCN11A genomic nucleic acid molecule or mRNA molecule, and in case of mRNA, optionally reverse transcribing mRNA into cDNA.Such assay may comprise, for example, determining the identity of these positions of specific SCN11A nucleic acid molecule.In some embodiments, the method is an in vitro method.
[0104] In some embodiments, the determination step, detection step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of an SCN11A genomic nucleic acid molecule, an SCN11A mRNA molecule, or an SCN11A cDNA molecule in a biological sample, wherein the portion that is sequenced contains one or more mutations that cause or are predicted to cause loss of function (partial or complete).
[0105] In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only the SCN11A genomic nucleic acid molecule is analyzed. In some embodiments, only the SCN11A mRNA is analyzed. In some embodiments, only the SCN11A cDNA derived from the SCN11A mRNA is analyzed.
[0106] Mutation-specific polymerase chain reaction techniques can be used to detect mutations such as SNPs in nucleic acid sequences, and mutation-specific primers can be used because DNA polymerase will not extend if there is a mismatch with the template.
[0107] In some embodiments, the nucleic acid molecule in the sample is mRNA, and the mRNA is reverse transcribed into cDNA prior to the amplification step. In some embodiments, the nucleic acid molecule is present in a cell taken from the subject.
[0108] In some embodiments, the assay involves contacting the biological sample with a primer or probe, such as a mutation-specific primer or a mutation-specific probe, that specifically hybridizes to an SCN11A variant genomic sequence, variant mRNA sequence, or variant cDNA sequence under stringent conditions but does not specifically hybridize to the corresponding SCN11A reference sequence, and determining whether hybridization occurs.
[0109] In some embodiments, the determination step, detection step, or sequence analysis comprises: a) amplifying at least a portion of an SCN11A nucleic acid molecule encoding an SCN11A polypeptide; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support containing a mutation-specific probe; and d) detecting the detectable label.
[0110] In some embodiments, the assay involves RNA sequencing (RNA-Seq). In some embodiments, the assay also involves reverse transcribing mRNA into cDNA, for example, by reverse transcription polymerase chain reaction (RT-PCR).
[0111] In some embodiments, the method utilizes probes and primers of sufficient nucleotide length to bind to the target nucleotide sequence and specifically detect and / or distinguish polynucleotides including SCN11A variant genomic nucleic acid molecules, variant mRNA molecules, or variant cDNA molecules. Hybridization or reaction conditions can be determined by the operator to achieve this result. The nucleotide length can be any length that is sufficient for use in an optimal detection method, including any assay described or exemplified herein. Such probes and primers can specifically hybridize to the target nucleotide sequence under highly stringent hybridization conditions. Although probes that are different from the target nucleotide sequence and retain the ability to specifically detect and / or distinguish the target nucleotide sequence can be designed by conventional methods, the probes and primers can have a perfect nucleotide sequence identity of consecutive nucleotides in the target nucleotide sequence. The probes and primers can have about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity or complementarity to the nucleotide sequence of the target nucleic acid molecule.
[0112] Illustrative examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing. Other methods include nucleic acid hybridization methods other than sequencing (fluorescence in situ hybridization (FISH)), including the use of labeled primers or probes on purified DNA, amplified DNA, and fixed cell preparations. In some methods, the target nucleic acid molecule may be amplified prior to or simultaneously with detection. Examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA). Other methods include, but are not limited to, ligase chain reaction, strand displacement amplification, and thermophilic SDA (tSDA).
[0113] Hybridization techniques can employ stringent conditions so that the probe or primer specifically hybridizes to its target. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target sequence detectably higher than other non-target sequences, for example, at least 2-fold, at least 3-fold, at least 4-fold, or more than background, including more than 10-fold above background. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence detectably higher (at least 2-fold) than other nucleotide sequences. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence detectably higher (at least 3-fold) than other nucleotide sequences. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence detectably higher (at least 4-fold) than other nucleotide sequences. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence to a detectably higher degree (greater than 10-fold over background) than other nucleotide sequences. Stringent conditions are sequence-dependent and will vary in different circumstances.
[0114] Suitable stringency conditions that promote DNA hybridization, such as 6× sodium chloride / sodium citrate (SSC) at about 45° C., followed by a 2× SSC wash at 50° C., are known or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. Typically, stringent conditions for hybridization and detection include conditions in which the salt concentration is less than about 1.5 M NaCl at pH 7.0-8.3. +ion, typically about 0.01 to 1.0 M Na + The conditions will be ionic concentration (or other salts) and temperature of at least about 30° C. for short probes (e.g., 10-50 nucleotides) and at least about 60° C. for longer probes (e.g., more than 50 nucleotides). Stringent conditions may be achieved by the addition of destabilizing agents such as formamide. Optionally, the wash buffer may contain about 0.1% to about 1% SDS. The duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash will be at least long enough to reach equilibrium.
[0115] In some embodiments, such isolated nucleic acid molecules comprise at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55 , at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 2000, at least about 3000, at least about 4000, or at least about 5000 nucleotides. In some embodiments, such isolated nucleic acid molecules comprise or consist of at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, or at least about 25 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 18 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 15 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of about 10 to about 35, about 10 to about 30, about 10 to about 25, about 12 to about 30, about 12 to about 28, about 12 to about 24, about 15 to about 30, about 15 to about 25, about 18 to about 30, about 18 to about 25, about 18 to about 24, or about 18 to about 22 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of about 18 to about 30 nucleotides.In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 15 nucleotides to at least about 35 nucleotides.
[0116] In some embodiments, such isolated nucleic acid molecules hybridize under stringent conditions to predicted loss-of-function variant nucleic acid molecules of SCN11A (e.g., genomic nucleic acid molecules, mRNA molecules and / or cDNA molecules). Such nucleic acid molecules can be used, for example, as probes, primers, mutation-specific probes, or mutation-specific primers as described or exemplified herein, including, but not limited to, primers, probes, antisense RNA, shRNA, and siRNA, each of which is described in more detail elsewhere herein and can be used in any of the methods described herein.
[0117] In some embodiments, the isolated nucleic acid molecule hybridizes to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a predicted loss-of-function variant nucleic acid molecule of SCN11A. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 100 nucleotides, or about 15 to about 35 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 100 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 35 nucleotides.
[0118] In some embodiments, the mutation-specific probe and the mutation-specific primer comprise DNA. In some embodiments, the mutation-specific probe and the mutation-specific primer comprise RNA.
[0119] In some embodiments, the probes and primers described herein (including mutation-specific probes and mutation-specific primers) have nucleotide sequences that specifically hybridize to any of the nucleic acid molecules disclosed herein, or their complements. In some embodiments, the probes and primers specifically hybridize to any of the nucleic acid molecules disclosed herein under stringent conditions.
[0120] In some embodiments, primers, including mutation-specific primers, can be used for next-generation sequencing or high-throughput sequencing. In some examples, primers, including mutation-specific primers, can be modified. In particular, primers can include various modifications that are used in different steps, such as Massive Parallel Signature Sequencing (MPSS), Polony sequencing, and 454 Pyrosequencing. Modified primers can be used in several steps of the process, including biotinylated primers in the cloning step and fluorescently labeled primers used in the bead loading and detection steps. Polony sequencing is typically performed using paired-end tag libraries, where each molecule of DNA template is approximately 135 bp in length. Biotinylated primers are used in the bead loading step and emulsion PCR. Fluorescently labeled degenerate nonamer oligonucleotides are used in the detection step. The adapters can contain 5'-biotin tags for immobilizing the DNA library on streptavidin-coated beads.
[0121] The probes and primers described herein can be used to detect nucleotide variations in any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein. The primers described herein can be used to amplify any predicted loss-of-function variant nucleic acid molecule of SCN11A or a fragment thereof.
[0122] In the context of this disclosure, "specifically hybridizes" means that a probe or primer (e.g., a mutation-specific probe or mutation-specific primer) does not hybridize to a nucleic acid sequence encoding an SCN11A reference-type genomic nucleic acid molecule, an SCN11A reference-type mRNA molecule, and / or an SCN11A reference-type cDNA molecule.
[0123] In some embodiments, the probe (such as, for example, a mutation-specific probe) comprises a label. In some embodiments, the label is a fluorescent label, a radioactive label, or biotin. The present disclosure also provides a support comprising a substrate that is bound to any one or more of the probes disclosed herein. A solid support is a solid-state substrate or support to which molecules such as any of the probes disclosed herein can be associated. A form of solid support is an array. Another form of solid support is an array detector. An array detector is a solid support to which multiple types of probes are coupled in an array, grid, or other organized pattern. A form of solid-state substrate is a microtiter dish, such as a standard 96-well type. In some embodiments, a multi-well glass slide can be used, which usually contains one array per well.
[0124] Genomic nucleic acid molecules, mRNA molecules, and cDNA molecules can be derived from any organism.For example, genomic nucleic acid molecules, mRNA molecules, and cDNA molecules can be human or orthologs from another organism, such as non-human mammals, rodents, mice, or rats.It is understood that gene sequences within a population can differ due to polymorphisms, such as single nucleotide polymorphisms.
[0125] Also provided herein is functional polynucleotide that can interact with the disclosed nucleic acid molecule.Examples of functional polynucleotide include, but are not limited to, antisense molecules, aptamers, ribozymes, triplex-forming molecules, and external guide sequences.Functional polynucleotides can act as effectors, inhibitors, modulators, and stimulators of the specific activity of target molecules, or functional polynucleotides can have de novo activity independent of any other molecules.
[0126] The isolated nucleic acid molecules disclosed herein may include RNA, DNA, or both RNA and DNA. The isolated nucleic acid molecules may also be linked or fused to heterologous nucleic acid sequences, for example in a vector, or to heterologous labels. For example, the isolated nucleic acid molecules disclosed herein may be present as exogenous donor sequences in or containing a vector that includes the isolated nucleic acid molecule and a heterologous nucleic acid sequence. The isolated nucleic acid molecules may also be linked or fused to heterologous labels. The labels may be directly detectable (e.g., fluorophores) or indirectly detectable (e.g., haptens, enzymes, or fluorophore quenchers). Such labels may be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radioactive labels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The labels may also be, for example, chemiluminescent, metal-containing, or enzymes (where enzyme-dependent secondary signal generation occurs). The term "label" may also refer to a "tag" or hapten that can selectively bind to the conjugated molecule such that the conjugated molecule is subsequently added with a substrate and used to generate a detectable signal. For example, biotin can be used as a tag to bind to the tag with an avidin or streptavidin conjugate of horseradish peroxidase (HRP), and a colorimetric substrate (such as tetramethylbenzidine (TMB)) or a fluorogenic substrate can be used to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3xFLAG, 6xHis or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, epitope tags, or the Fc portion of an immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes and their colorimetric, fluorescent, and chemiluminescent substrates, as well as other labels.
[0127] Percent identity (or percent complementarity) between specific stretches of nucleotide sequences in nucleic acid molecules or amino acid sequences in polypeptides can be routinely determined using the BLAST program (base local sequence comparison search tool) and PowerBLAST program (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656), or the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.) using default settings that use the Smith and Waterman algorithm (Adv. Appl. Math., 1981, 2, 482-489). When referring to percent sequence identity herein, higher sequence identity percentages are preferred over lower ones.
[0128] The present disclosure also provides a headache or migraine treating, preventing, or suppressing therapeutic agent for use in treating and / or preventing headache or migraine in a subject having a predicted loss-of-function variant nucleic acid molecule of SCN11A. Any of the headache or migraine treating, preventing, or suppressing therapeutic agents described herein can be used in these methods. Any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein can be used in these methods.
[0129] The present disclosure also provides the use of a therapeutic agent for treating, preventing, or suppressing headache or migraine for use in the preparation of a medicament for treating and / or preventing headache or migraine in a subject having a predicted loss-of-function variant nucleic acid molecule of SCN11A. Any of the therapeutic agents for treating, preventing, or suppressing headache or migraine described herein can be used in these methods. Any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein can be used in these methods.
[0130] The present disclosure also provides an SCN11A inhibitor for use in treating and / or preventing headache or migraine in a subject who is SCN11A reference type or heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A.Any of the SCN11A inhibitors described herein can be used in these methods.Any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein can be used in these methods.
[0131] The present disclosure also provides an SCN11A inhibitor in the preparation of a medicament for treating and / or preventing headache or migraine in a subject who is SCN11A reference type or heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A. Any of the SCN11A inhibitors described herein can be used in these methods. Any of the predicted loss-of-function variant nucleic acid molecules of SCN11A disclosed herein can be used in these methods.
[0132] All patent documents, websites, other publications, accession numbers, etc. cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference as such. Where various versions of a sequence are associated with accession numbers at different times, the version associated with the accession number at the effective filing date of this application is meant. Effective filing date means the earlier of the actual filing date or the filing date of the priority application that refers to the accession number, if applicable. Similarly, where different versions of publications, websites, etc. are published at different times, the version last published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure may be used in combination with any other feature, step, element, embodiment, or aspect, unless otherwise indicated. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
[0133] The following examples are provided to further illustrate the embodiments. They are intended to illustrate, not limit, the claimed embodiments. The following examples provide those skilled in the art with disclosure and description of how the compounds, compositions, articles, devices, and / or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some error and deviation can be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric pressure. EXAMPLES
[0134] Example 1: Meta-analysis of headache and migraine A meta-analysis of headache and migraine was performed across four cohorts (UK Biobank, Geisinger, Malmo diet and cancer study, and Mt. Sinai BioMe Biobank). A set of rare predicted loss-of-function variants (minor allele frequency (MAF<1%)) in SCN11A was identified to be associated with protection from headache and migraine (see Table 1), suggesting that downregulating or inhibiting SCN11A may protect against headache and migraine.
[0135] [Table 3]
[0136] In addition to those described herein, various modifications of the described subject matter will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, etc.) is hereby incorporated by reference in its entirety and for all purposes.
Claims
1. 1. A method of treating a subject having or at risk of developing a headache, said method comprising administering to said subject a sodium voltage-dependent channel alpha subunit 11 (SCN11A) inhibitor.
2. 1. A method of treating a subject having or at risk of developing a migraine headache, the method comprising administering to the subject a sodium voltage-dependent channel alpha subunit 11 (SCN11A) inhibitor.
3. The method of claim 1 or claim 2, wherein the SCN11A inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an SCN11A nucleic acid molecule.
4. The method of claim 3 , wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).
5. The method of claim 1 or claim 2, wherein the SCN11A inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an SCN11A genomic nucleic acid molecule.
6. 6. The method of claim 5, wherein the Cas protein is Cas9 or Cpf1.
7. 7. The method of claim 5 or claim 6, wherein the gRNA comprises about 17 to about 23 nucleotides.
8. The method of claim 1 or claim 2, wherein the SCN11A inhibitor comprises a small molecule.
9. The method of claim 1 or claim 2, wherein the SCN11A inhibitor comprises an antibody.
10. The method of any one of claims 1 to 9, further comprising detecting the presence or absence of a predicted loss-of-function variant nucleic acid molecule of SCN11A in a biological sample from the subject.
11. 11. The method of claim 10, further comprising administering to the subject a standard dose of a therapeutic agent that treats, prevents, or suppresses headache or migraine, and wherein the predicted loss-of-function variant nucleic acid molecule of SCN11A is not present in the biological sample.
12. The method of claim 10, further comprising administering a therapeutic agent for treating, preventing, or suppressing headache or migraine to a subject who is heterozygous for the predicted loss-of-function variant nucleic acid molecule of SCN11A at a dose equal to or less than a standard dose.
13. The method of any one of claims 10 to 12, wherein the SCN11A predicted loss-of-function variant nucleic acid molecule is a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated SCN11A predicted loss-of-function polypeptide.
14. 1. A method of treating a subject with a therapeutic agent that treats or inhibits headache or migraine by administering a therapeutic agent that prevents headache or migraine, the subject having a headache or migraine or at risk of developing a headache or migraine, the method comprising: determining whether the subject has a predicted loss-of-function variant nucleic acid molecule of sodium voltage-dependent channel alpha subunit 11 (SCN11A); obtaining or having obtained a biological sample from said subject; performing or has performed sequence analysis on the biological sample to determine whether the subject has a genotype that includes a predicted loss-of-function variant nucleic acid molecule of SCN11A; administering or continuing to administer to the subject, who is an SCN11A reference type, a standard dose of said therapeutic agent that treats, prevents, or suppresses said headache or said migraine, and / or administering to said subject an SCN11A inhibitor; administering or continuing to administer to a subject who is heterozygous for the predicted loss-of-function variant nucleic acid molecule of SCN11A the therapeutic agent for treating, preventing, or suppressing the headache or migraine at an amount equal to or less than a standard dose, and / or administering to the subject an SCN11A inhibitor; administering or continuing to administer to a subject homozygous for said SCN11A predicted loss-of-function variant nucleic acid molecule said therapeutic agent for treating, preventing, or suppressing said headache or said migraine at an amount equal to or less than a standard dose; The method of treatment, wherein the presence of a genotype having a predicted loss-of-function variant nucleic acid molecule of SCN11A indicates that the subject is at low risk of developing headache or migraine.
15. The method of claim 14, wherein the subject is SCN11A reference type and the subject is administered or continues to be administered a standard dose of the therapeutic agent that treats, prevents, or suppresses the headache or migraine, and the SCN11A inhibitor is administered.
16. The method of claim 14, wherein the subject is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A, and the subject is administered or continues to be administered the therapeutic agent that treats, prevents, or suppresses the headache or migraine at a standard dose or less, and the SCN11A inhibitor is administered.
17. The method of any one of claims 14 to 16, wherein the SCN11A predicted loss-of-function variant nucleic acid molecule is a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated SCN11A predicted loss-of-function polypeptide.
18. The method of any one of claims 14 to 17, wherein the SCN11A inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an SCN11A nucleic acid molecule.
19. 20. The method of claim 18, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).
20. The method of any one of claims 14 to 17, wherein the SCN11A inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an SCN11A genomic nucleic acid molecule.
21. 21. The method of claim 20, wherein the Cas protein is Cas9 or Cpf1.
22. 22. The method of claim 20 or claim 21, wherein the gRNA comprises from about 17 to about 23 nucleotides.
23. The method of any one of claims 14 to 17, wherein the SCN11A inhibitor comprises a small molecule.
24. The method of any one of claims 14 to 17, wherein the SCN11A inhibitor comprises an antibody.
25. The method of any one of claims 14 to 24, wherein the subject has a headache or is at risk of developing a headache.
26. 26. The method of claim 25, wherein the therapeutic agent is selected from nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, diclofenac, fenoprofen, indomethacin, ketorolac tromethamine, meclofenamate sodium, diflunisal, tolmetin, ketoprofen, and flurbiprofen, or any combination thereof.
27. The method of any one of claims 14 to 24, wherein the subject has a migraine headache or is at risk of developing a migraine headache.
28. 28. The method of claim 27, wherein the therapeutic agent is selected from nonsteroidal anti-inflammatory drugs, acetaminophen, triptans, ergots, calcitonin gene-related peptide (CGRP) receptor antagonists, anti-nausea drugs, hypertensive drugs, antidepressants, anti-epileptic drugs, and Botox, or any combination thereof.
29. 1. A method for identifying a subject at high risk of developing a headache or migraine, the method comprising: determining, or having determined, the presence or absence of a predicted loss-of-function variant nucleic acid molecule of sodium voltage-dependent channel alpha subunit 11 (SCN11A) in a biological sample obtained from the subject; In that case, if the subject is of the SCN11A reference type, the subject has an increased risk of developing a headache or migraine; The method of identifying, wherein if the subject is heterozygous or homozygous for a nucleic acid molecule of a predicted loss-of-function variant of SCN11A, the subject has a low risk of developing headache or migraine.
30. 30. The method of claim 29, wherein the SCN11A predicted loss-of-function variant nucleic acid molecule is a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated SCN11A predicted loss-of-function polypeptide.
31. The method of claim 29 or claim 30, further comprising administering to a subject who is SCN11A reference type a standard dose of a therapeutic agent that treats, prevents, or suppresses the headache or migraine, and / or administering an SCN11A inhibitor.
32. The method of claim 29 or claim 30, further comprising administering to a subject who is heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A a therapeutic agent for treating, preventing, or suppressing the headache or migraine in an amount equal to or less than a standard dose, and / or administering an SCN11A inhibitor.
33. The method of claim 31 or claim 32, wherein the SCN11A inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an SCN11A nucleic acid molecule.
34. 34. The method of claim 33, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).
35. The method of claim 31 or 32, wherein the SCN11A inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an SCN11A genomic nucleic acid molecule.
36. 36. The method of claim 35, wherein the Cas protein is Cas9 or Cpf1.
37. 37. The method of claim 35 or claim 36, wherein the gRNA comprises from about 17 to about 23 nucleotides.
38. The method of claim 31 or claim 32, wherein the SCN11A inhibitor comprises a small molecule.
39. The method of claim 31 or claim 32, wherein the SCN11A inhibitor comprises an antibody.
40. 33. The method of claim 31 or claim 32, wherein the subject is at risk of developing a headache.
41. 41. The method of claim 40, wherein the therapeutic agent is selected from nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, diclofenac, fenoprofen, indomethacin, ketorolac tromethamine, meclofenamate sodium, diflunisal, tolmetin, ketoprofen, and flurbiprofen, or any combination thereof.
42. 33. The method of claim 31 or claim 32, wherein the subject is at risk of developing a migraine headache.
43. 43. The method of claim 42, wherein the therapeutic agent is selected from nonsteroidal anti-inflammatory drugs, acetaminophen, triptans, ergots, calcitonin gene-related peptide (CGRP) receptor antagonists, anti-nausea drugs, hypertensive drugs, antidepressants, anti-epileptic drugs, and Botox, or any combination thereof.
44. A therapeutic agent for treating, preventing, or suppressing headache or migraine, for use in treating and / or preventing headache or migraine in a subject having a predicted loss-of-function variant nucleic acid molecule of sodium voltage-dependent channel alpha subunit 11 (SCN11A).
45. 45. The method of claim 44, wherein the SCN11A predicted loss-of-function variant nucleic acid molecule is a splice site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant encoding a truncated SCN11A predicted loss-of-function polypeptide.
46. A sodium voltage-dependent channel alpha subunit 11 (SCN11A) inhibitor for use in the treatment and / or prevention of headache or migraine in a subject who is SCN11A reference type or heterozygous for a predicted loss-of-function variant nucleic acid molecule of SCN11A.
47. The method of claim 46, wherein the SCN11A inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an SCN11A nucleic acid molecule.
48. 48. The method of claim 47, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).
49. 47. The method of claim 46, wherein the SCN11A inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an SCN11A genomic nucleic acid molecule.
50. 50. The method of claim 49, wherein the Cas protein is Cas9 or Cpf1.
51. 51. The method of claim 49 or claim 50, wherein the gRNA comprises from about 17 to about 23 nucleotides.
52. 47. The method of claim 46, wherein the SCN11A inhibitor comprises a small molecule.
53. 47. The method of claim 46, wherein the SCN11A inhibitor comprises an antibody.
